[Monoclonal antibodies: also for dermatologists!]
Anticorps monoclonaux thérapeutiques - En dermatologie aussi !
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
Therapeutic monoclonal antibodies are henceforth commonly used in the management of psoriasis but have been also used more recently in chronic spontaneous urticaria and atopic dermatitis. Three examples are developed herein: dupilumab, omalizumab and lanadelumab. The specificity of their mechanism of action results from a better understanding of the inflammatory pathways in these chronic diseases, which previously shared either the same targeted topical or systemic treatments. However, their high costs should be put into perspective with the epidemiology, the precise evaluation of the severity, the optimization of first line treatments and the long-term benefit/risk ratio. Anticorps monoclonaux thérapeutiques - En dermatologie aussi ! Les anticorps monoclonaux thérapeutiques en dermatologie ont d’abord été utilisés pour la prise en charge du psoriasis, puis, plus récemment, de l’urticaire chronique spontanée et de la dermatite atopique. Trois exemples seront abordés dans cette revue: le dupilumab, l’omalizumab et le lanadélumab. Leur mode d’action spécifique résulte d’une meilleure compréhension des mécanismes inflammatoires de ces maladies chroniques qui partageaient autrefois des traitements topiques ou systémiques plus ou moins ciblés. Leur utilisation onéreuse doit cependant être raisonnée par la mise en perspective de l’épidémiologie, de l’évaluation précise de la sévérité, de l’optimisation des traitements de première ligne, et de la balance bénéfices/risques.
Autres résumés
Type: Publisher
(fre)
Anticorps monoclonaux thérapeutiques - En dermatologie aussi !
Identifiants
pubmed: 31903911
doi: 10.1051/medsci/2019201
pii: msc190174
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
lanadelumab
2372V1TKXK
dupilumab
420K487FSG
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
1017-1021Informations de copyright
© 2019 médecine/sciences – Inserm.
Références
Jaddo. Juste après dresseuse d’ours: les histoires brutes et non romancées d’une jeune médecin généraliste. Paris: Fleuve Éditions, 2011: 304 p.
Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009 ; 10: 816–824.
Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « objectifs peau » study. J Eur Acad Dermatol Venereol 2018 ; 32: 1967–1971.
Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: A systematic review and meta-analysis. JAMA Dermatol 2019 ; 155: 178–187.
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015 ; 74: 480–489.
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016 ; 387: 1109–1122.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 ; 375: 2335–2348.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (liberty ad chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017 ; 389: 2287–2303.
Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019 ; 81: 143–151.
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018 ; 32: 850–878.
O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 ; 136: 197–201.
Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015 ; 135: 337–342.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015 ; 135: 67–75.
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013 ; 368: 924–935.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013 ; 132: 101–109.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018 ; 73: 1393–1414.
Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014 ; 69: 602–616.
Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018 ; 320: 2108–2121.
de Bruin-Weller M.. Time to get rid of the investigator’s global assessment as the primary outcome for clinical trials in atopic dermatitis ?. Br J Dermatol 2019 ; 181: 12–13.